Cantargia AB Cash Flow Conversion Efficiency
Cantargia AB cash flow conversion efficiency. Based on the latest financial reports, Cantargia AB (CANTA) has a cash flow conversion efficiency ratio of 0.943x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr280.72 Million ≈ $30.21 Million USD) by net assets (Skr297.57 Million ≈ $32.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Cantargia AB (2011–2024)
Cash flow conversion efficiency of Cantargia AB from 2011 to 2024. This chart illustrates how Cantargia AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Cantargia AB for real-time trading data and today's change.
Cantargia AB Cash Flow Conversion Ratio Explained
Cantargia AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Cantargia AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cantargia AB ranked by their cash flow conversion efficiency. Also see CANTA market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
IBKS No. 15 Special Purpose Acquisition Co. Ltd.
KQ:373200
|
-0.069x |
|
TOVIS Co.Ltd
KQ:051360
|
0.035x |
|
Li Cheng Enterprise Co Ltd
TW:4426
|
-0.022x |
|
Plastiques du Val de Loire
PA:PVL
|
0.215x |
|
TPXIMPACT HOLDINGS LS-01
F:9L7
|
N/A |
|
Aman Agrindo
JK:GULA
|
0.010x |
|
Senko Co. Ltd
KQ:347000
|
0.022x |
|
Kwang Ming Silk Mill Co Ltd
TWO:4420
|
-0.105x |
Annual Cash Flow Conversion Efficiency for Cantargia AB (2011–2024)
The table below shows the annual cash flow conversion efficiency of Cantargia AB from 2011 to 2024. Review cash generation quality of Cantargia AB to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr116.30 Million ≈ $12.52 Million |
Skr-162.75 Million ≈ $-17.51 Million |
-1.399x | +17.63% |
| 2023-12-31 | Skr168.74 Million ≈ $18.16 Million |
Skr-286.66 Million ≈ $-30.85 Million |
-1.699x | -84.45% |
| 2022-12-31 | Skr389.68 Million ≈ $41.94 Million |
Skr-358.92 Million ≈ $-38.62 Million |
-0.921x | -41.63% |
| 2021-12-31 | Skr532.75 Million ≈ $57.33 Million |
Skr-346.44 Million ≈ $-37.28 Million |
-0.650x | -270.89% |
| 2020-12-31 | Skr891.93 Million ≈ $95.99 Million |
Skr-156.39 Million ≈ $-16.83 Million |
-0.175x | +77.58% |
| 2019-12-31 | Skr142.27 Million ≈ $15.31 Million |
Skr-111.25 Million ≈ $-11.97 Million |
-0.782x | -15.81% |
| 2018-12-31 | Skr155.04 Million ≈ $16.69 Million |
Skr-104.69 Million ≈ $-11.27 Million |
-0.675x | -304.30% |
| 2017-12-31 | Skr246.12 Million ≈ $26.49 Million |
Skr-41.10 Million ≈ $-4.42 Million |
-0.167x | +84.31% |
| 2016-12-31 | Skr37.13 Million ≈ $4.00 Million |
Skr-39.53 Million ≈ $-4.25 Million |
-1.065x | +1.35% |
| 2015-12-31 | Skr28.05 Million ≈ $3.02 Million |
Skr-30.28 Million ≈ $-3.26 Million |
-1.079x | -164.11% |
| 2014-12-31 | Skr4.10 Million ≈ $440.95K |
Skr6.90 Million ≈ $742.32K |
1.683x | +163.81% |
| 2013-12-31 | Skr3.13 Million ≈ $337.02K |
Skr-8.26 Million ≈ $-889.18K |
-2.638x | -114.81% |
| 2012-12-31 | Skr3.08 Million ≈ $331.15K |
Skr-3.78 Million ≈ $-406.73K |
-1.228x | +35.02% |
| 2011-12-31 | Skr1.54 Million ≈ $165.99K |
Skr-2.92 Million ≈ $-313.74K |
-1.890x | -- |
About Cantargia AB
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which… Read more